These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2533895)

  • 1. The clinical pharmacology of ondansetron.
    Blackwell CP; Harding SM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S21-4; discussion S25-7. PubMed ID: 2533895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimes.
    Schmoll HJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S35-9. PubMed ID: 2533897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron metabolism and pharmacokinetics.
    Pritchard JF
    Semin Oncol; 1992 Aug; 19(4 Suppl 10):9-15. PubMed ID: 1387254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The metabolism of ondansetron.
    Saynor DA; Dixon CM
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S75-7. PubMed ID: 2533904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of ondansetron.
    Smith RN
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S47-50; discussion S51-4. PubMed ID: 2533899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probable involvement of the 5-hydroxytryptamine(4) receptor in methotrexate-induced delayed emesis in dogs.
    Yamakuni H; Sawai H; Maeda Y; Imazumi K; Sakuma H; Matsuo M; Mutoh S; Seki J
    J Pharmacol Exp Ther; 2000 Mar; 292(3):1002-7. PubMed ID: 10688616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness.
    Levine ME; Chillas JC; Stern RM; Knox GW
    Aviat Space Environ Med; 2000 Nov; 71(11):1111-4. PubMed ID: 11086664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ondansetron: a novel antiemetic agent.
    Figg WD; Graham CL; Hak LJ; Dukes GE
    South Med J; 1993 May; 86(5):497-502. PubMed ID: 8488393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical studies with ondansetron in the control of radiation-induced emesis.
    Priestman TJ
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S29-33. PubMed ID: 2533896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ondansetron in the prophylaxis of acute cisplatin-induced nausea and vomiting.
    Marty M
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S41-5. PubMed ID: 2533898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical development of ondansetron tablets.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S63-6. PubMed ID: 2533901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron.
    Villikka K; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Apr; 65(4):377-81. PubMed ID: 10223773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation].
    Jeremić B
    Srp Arh Celok Lek; 1996; 124(5-6):131-4. PubMed ID: 9102832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioavailability studies of generic ondansetron, and the innovator preparation, in healthy Thai male volunteers.
    Rojanasthien N; Manorot M; Kumsorn B; Nawoot S; Teekachunhatean S; Sangdee C; Apisariyakul A
    J Med Assoc Thai; 1999 Jul; 82(7):713-20. PubMed ID: 10511774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
    Shah AK; Hunt TL; Gallagher SC; Cullen MT
    Curr Med Res Opin; 2005 Apr; 21(4):595-601. PubMed ID: 15899109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
    Cunningham RS
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiemetic effect of ondansetron and dexamethasone in gynecologic malignant patients receiving chemotherapy.
    Pradermdee P; Manusirivithaya S; Tangjitgamol S; Thavaramara T; Sukwattana P
    J Med Assoc Thai; 2006 Oct; 89 Suppl 4():S29-36. PubMed ID: 17725140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-HT3 receptor antagonists ameliorate emesis in the ferret evoked by neutron or proton radiation.
    King GL; Rabin BM; Weatherspoon JK
    Aviat Space Environ Med; 1999 May; 70(5):485-92. PubMed ID: 10332945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.